Department of Chronic and Metabolic diseases, KU Leuven, Leuven, Belgium.
Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
Infect Dis (Lond). 2024 Oct;56(10):870-879. doi: 10.1080/23744235.2024.2361795. Epub 2024 Jun 7.
The rising incidence of immune-mediated inflammatory diseases (IMID) requires innovative management strategies, including effective vaccination. We aimed to assess the impact of an electronic medical record (EMR)-integrated vaccination tool on vaccination coverage among patients with inflammatory bowel diseases (IBD), rheumatological and dermatological conditions.
A prospective observational study compared vaccination coverage before (2018) and after (2021) implementing the module. Vaccination data for influenza, pneumococcus, hepatitis B and tetanus, and potential predictors were collected from 1430 IMID patients (44.9% male, median age (interquartile range [IQR]) 54 (40-66) years, 789 with IBD, 604 with rheumatological and 37 with dermatological conditions). Data were analysed using McNemar, chi-square tests and multinominal logistic regression.
Significant increases in pneumococcus (56.6% to 73.1%, < .001) and hepatitis B vaccination (62.2% to 75.9%, < .001) were observed. Influenza vaccination rates increased among IBD (76.2% to 80.5%, = .006) but remained stable overall (73.1% to 73.2%, = 1.000). Tetanus vaccination rates decreased (71.5% to 55.0%, < .001). The proportion of fully vaccinated patients (against influenza in the past year for patients >50 years old and/or under immunosuppressive therapy, against pneumococcus in the past 5 years for patients >65 years old and/or under immunosuppressive therapy and additionally against hepatitis B for IBD patients) rose from 41.3% to 54.8% ( < .001 all using McNemar). Factors associated with vaccinations included age, immunosuppressive therapy and education level.
Increased vaccination coverage was measured after implementing the vaccination tool. The COVID19 pandemic and the 2018 measurement might have increased vaccination awareness. Education of patients and healthcare professionals remains crucial.
免疫介导的炎症性疾病(IMID)发病率不断上升,需要创新的管理策略,包括有效的疫苗接种。我们旨在评估电子病历(EMR)整合疫苗接种工具对炎症性肠病(IBD)、风湿病和皮肤病患者疫苗接种覆盖率的影响。
一项前瞻性观察研究比较了实施模块前后(2018 年和 2021 年)的疫苗接种覆盖率。从 1430 名 IMID 患者(44.9%为男性,中位年龄(四分位距[IQR])54(40-66)岁,789 名患有 IBD、604 名患有风湿病和 37 名患有皮肤病)收集流感、肺炎球菌、乙型肝炎和破伤风疫苗接种数据以及潜在预测因素。使用 McNemar、卡方检验和多项逻辑回归分析数据。
观察到肺炎球菌(56.6%至 73.1%, < .001)和乙型肝炎疫苗接种(62.2%至 75.9%, < .001)显著增加。IBD 患者的流感疫苗接种率增加(76.2%至 80.5%, = .006),但总体保持稳定(73.1%至 73.2%, = 1.000)。破伤风疫苗接种率下降(71.5%至 55.0%, < .001)。完全接种疫苗的患者比例(过去一年对年龄大于 50 岁且/或接受免疫抑制治疗的患者接种流感疫苗,过去 5 年对年龄大于 65 岁且/或接受免疫抑制治疗的患者接种肺炎球菌疫苗,以及对 IBD 患者接种乙型肝炎疫苗)从 41.3%增加到 54.8%(所有使用 McNemar 的均 < .001)。与疫苗接种相关的因素包括年龄、免疫抑制治疗和教育水平。
实施疫苗接种工具后,疫苗接种覆盖率增加。COVID19 大流行和 2018 年的测量可能提高了疫苗接种意识。患者和医疗保健专业人员的教育仍然至关重要。